Tools for Tracking Antibiotic Resistance by Lubick, Naomi
News | Spheres of Influence Spheres of Influence | Tools for Tracking Antibiotic Resistance
Environmental Health Perspectives  •  v o l u m e  119 | n u m b e r  5 | May 2011   A 215
W
hen a team of researchers from Sweden first 
started measuring chemicals in a river near 
Patancheru, India, they found shocking 
concentrations of drugs flowing downstream—
for example, levels of the potent antibiotic 
ciprofloxacin greater than those found in the blood of humans taking 
the drug. A major source of these drugs was treated wastewater from 
pharmaceutical manufacturing plants that was discharged into the 
river and surrounding environs, as Joakim Larsson and his colleagues 
from the University of Gothenburg reported several years ago.
1 An 
update published in PLoS ONE
2 now links the drugs with downstream 
development of microbes with genetic resistance to multiple antibiotics 
typically used to treat human illness. 
The researchers found snippets of genetic material in bacteria from 
river sediments downstream of the treatment plant that conferred resis-
tance not only to ciprofloxacin, a fluoroquinolone, but also to betalac-
tams, aminoglycosides, sulfonamides, and other classes of antibiotics. 
Several genes that provide resistance to ciprofloxacin and have the ability 
to transfer between different bacteria were extremely common at some of 
the sampling sites.
2
What if the bacteria in Patancheru could develop ways to survive 
the daily onslaught of ciprofloxacin, most likely over the course of years 
in their river environment, and ended up passing on their new genetic 
resistance to pathogenic bacteria that could be a threat to human health? 
Although Larsson’s team has yet to catalog antibiotic resistance in the 
local population, people in the region are continually exposed to resistant 
microbes as they use the river water for agriculture and everyday home 
life. “This is a huge scary experiment in nature,” Larsson says.
Just how isolated these kinds of drug “hot spots” are remains 
unknown, although researchers have pressed for global monitoring of 
antibiotic use and resistance for the past several decades, across disciplines 
as diverse as clinical medicine and ecotoxicity. Bringing together these 
fields reflects the breadth of challenges in tracking antibiotic resistance, 
but new technologies and ideas hold promise for the near future.
Overcoming a Lack of Coordination
“Misuse of antibiotics is obviously what creates the basic factors that 
produce drug resistance,” says Mario Raviglione, director of the World 
Health Organization (WHO) department charged with tuberculosis 
control; this is true in both the developing and developed worlds. And 
despite educational campaigns by the U.S. Centers for Disease Control 
and Prevention (CDC)
3 and others aimed at improving clinicians’ use 
of antibiotics, overprescribing remains a problem for multiple reasons.
4 
Moreover, patient compliance—for example, taking the full course 
of prescribed antibiotics—can be lax, which leads to the evolution of 
more antibiotic-resistant pathogens.
Agricultural use of human drugs adds to the threat of drug resis-
tance. After World War II, antibiotics started to be used for purposes 
such as growth promotion in livestock. Since then, antibiotics—and in 
some cases, the genes for resistance to multiple drugs—have been found 
on industrial cattle, swine, and shrimp farms,
5,6,7,8 measured on chicken 
skins in grocery stores,
9 and even detected in apple orchards sprayed with 
drugs originally intended for human use.
10 
For World Health Day in April 2011 the WHO chose the theme 
of the global spread of antibiotic resistance, marking a little over 
a decade since the organization first called for patient and doctor 
guidelines to protect antibiotics from becoming obsolete.
11 A docu-
ment issued by the WHO in 2001 put forth a series of recommenda-
tions for patients and the general community, prescribers and dispens-
ers, hospitals, agricultural enterprises, national governments and health 
systems, and drug developers and promoters.
12 However, in general 
“very few countries, if any, have made a comprehensive effort to do 
any of the measures included in the older guidelines,” says Raviglione, 
who led preparations for World Health Day 2011. “Why are countries 
not picking them up? Lack of resources? Their health systems are not 
strong enough? The cost of drugs?” 
On 7 April 2011 the organization released updated policy guid-
ance for countries to curb the spread of antibiotic resistance in health 
care settings.
13 Some of this guidance is aimed at doctors and hospitals, 
while some is geared toward policy makers and legislators. The simple 
package of policy recommendations is intended to be easy for coun-
tries to adopt, Raviglione says. The WHO-level focus on antibiotic 
resistance issues also gives health ministers around the world a platform 
from which to call for funding and research attention at home.
But individual countries cannot handle this issue acting alone. 
During its 2009 presidency of the European Union, the Swedish gov-
ernment highlighted antibiotic resistance, focusing the conversation on 
solutions across Europe.
14 For instance, a September 2009 meeting tar-
geted industry, policy makers, and others focused on finding incentives 
for creating new drugs.
15 Meanwhile, in the United States, the U.S. 
Food and Drug Administration (FDA) in 2010 issued draft guidance 
urging the judicious use of medically important antibiotics in live-
stock.
16 The 2011–2015 Strategic Plan of the National Antimicrobial 
Resistance Monitoring System, a collaboration between the FDA, 
CDC, U.S. Department of Agriculture, and state and local health 
departments, includes efforts to strengthen sampling, reporting, and 
international and domestic collaborative efforts.
17 
Bills aimed at addressing antibiotic resistance were introduced in 
2009 in the House of Representatives
18 and the Senate,
19 but foundered. 
This year, Louise Slaughter (D–NY) tried again in the House, introduc-
ing H.R. 965, the Preservation of Antibiotics for Medical Treatment 
Act of 2011
20 on March 9. Another bill in the House, H.R. 6331, the 
Generating Antibiotic Incentives Now Act of 2010,
21 would create 
incentives to bring new antibiotics to market by speeding up the approv-
al process. These bills have lingered in committee, even as the problem 
continues to grow globally. 
Traveling Wild
The antibiotic drug hot spot in India is not alone: researchers have 
traced drugs flowing downstream from manufacturers in China and 
Cuba
22 and from wastewater treatment plants in the United States.
23,24 
They also have identified antimicrobial resistance genetic material 
in treated waste effluent and tap water in Michigan and Ohio,
25,26 
and researchers in Sweden recently documented multidrug-resistant 
Escherichia coli in the waste of migrating birds in the Arctic.
27 
Given the widespread presence of antibiotics in the natural 
environment,
28 it should not be a surprise that resistance is growing in 
wild bacteria and microbes—but is that resistance transferable to patho-
gens relevant to human health? Eventually the answer will most certainly 
be yes: Bacteria, microbes, and even fungi under stress from high con-
centrations of drugs might have the ability to replicate DNA snippets 
and possibly pass them on to other microbial species in the environment, 
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says Dave Ussery, an associate professor of 
microbial genomics at the Technical University 
of Denmark. Transported in the integrons, 
plasmids, and other cellular genetic modules 
that confer resistance, these snippets can be 
traded like baseball cards among microbes.
29
The locations and impacts of reservoirs 
of antibiotic resistance in the wild remain 
enigmatic,
30  and  not  only  for  humans. 
Antibiotic drugs and any acquired resistance to 
them might, for example, affect how microbes 
communicate with each other through “quo-
rum sensing,” a protein signaling feedback loop 
key to microbial population dynamics.
31 
But until recently, truly wild settings 
have garnered less interest from researchers, 
policy makers, and media  than agricultural 
exposures—for example, farmers who handle 
pigs treated with multiple drugs and then end 
up with resistant strains on their skin,
32 includ-
ing methicillin-resistant Staphylococcus aureus. 
Researchers from the U.S. Geological 
Survey led by Dana Kolpin also are looking at 
animal waste for how much residual concentra-
tion of antibiotic it might carry and the poten-
tial impacts on microbial life if the manure is 
spread on agricultural fields or released acci-
dentally. Results of Kolpin’s research are not 
yet available, but a small-scale study by another 
group tracking resistance genes from biosolids 
and manure at two soil sites has shown the 
genes—with resistance for tetracycline and sul-
fanomides—transfer at different rates depend-
ing on soil type.
33
Kink in the Pipeline 
Another worry underlying the issue of resis-
tance is the fact that pharmaceutical compa-
nies are not discovering new antibiotics. At 
least three reasons explain why the pipeline 
is so empty, says Ingrid Petersson, director of 
science relations at pharmaceutical company 
AstraZeneca. First, finding new pathways in 
microbes or pinpointing proteins to create 
new antibiotics is difficult, in part because of 
what could be considered an embarrassment 
of possibilities with too many unknowns. 
Second, she says, the regulatory environment 
is complicated: getting a drug through approv-
al processes takes a long time and costs a lot of 
money, among other factors. And third, low 
prices for existing antibiotics—many of which 
are generics—do not encourage companies to 
invest in new drugs. 
“Existing, older antibiotics are cheaper, 
which makes it difficult to achieve realistic 
prices for new antibiotics—prices which would 
provide a viable return on investment,” explains 
Colin Mackay, director of communication and 
partnerships for the European Federation of 
the Pharmaceutical Industries and Associations, 
a trade organization. “Furthermore, antibiot-
ics are only used acutely, perhaps only for a 
week to ten days at a time. This adds to the 
difficulty in making a return on investment. 
By comparison, treatments for chronic illness-
es, say for cardiovascular or musculoskeletal 
conditions, are used long term, perhaps for the 
rest of the patient’s life.”
“Drug development . . . is one of the 
most critical things that we are facing,” says 
Otto Cars, the chairman of ReAct (Action on 
Antibiotic Resistance), an independent think 
tank, and a professor of infectious diseases 
at Uppsala University. For gut flora that can 
shift readily from animal to human hosts—
including Gram-negative
34 enterics such as 
Salmonella, Campylobacter, Klebsiella, E. coli, 
and Shigella—horizontal gene transfer is “mov-
ing rapidly now,” he says. “These kinds of 
infections that Gram-negative bacteria are 
causing are already untreatable; even in the 
rich part of the world, there are totally resistant 
strains,” he says. “The drug pipeline is particu-
larly empty for that space.”
Nevertheless, some major companies 
are looking into new antibiotics. For exam-
ple, AstraZeneca is looking for solutions 
for  multidrug-resistant  tuberculosis.
35,36 
Companies  are  investing  money,  some-
times by acquiring smaller companies that 
have begun the research or joining in efforts 
with nonprofits
37 and academic researchers. 
Petersson notes that the Trans Atlantic Task 
Force on Antimicrobial Resistance,
38 formed 
between the European Union and the United 
States as part of the 2009 EU–US Summit 
Declaration,
39 will present suggestions at this 
year’s summit meeting for areas of cooperation, 
including incentives for industry to pursue new 
drug development.
The WHO, the CDC, and other national, 
international, and nonprofit organizations 
are pursuing alternative business models. 
Government funding, as when a federal agency 
invests in vaccine research, may be one option, 
Cars suggests. So-called advanced market com-
mitments—where governments pledge to pur-
chase drugs, thus guaranteeing a market—is 
another option. In its new policy guidance,
13 
the WHO calls for global and national com-
mitments to develop drugs and share informa-
tion on the national costs of inaction, as well 
as “push” and “pull” incentives to reduce the 
inherent risks in the initial phases of research 




40,41,42 for better management 
of the drugs currently available to doctors 
will require much more attention to trends 
of resistance. In particular, monitoring is now 
lacking. “If anything, we don’t know enough 
about developing countries to understand the 
situation—what resistant bacteria are there? 
In Europe and the U.S., systems of surveil-
lance are in place, but not in most of Africa 
or Asia,” Raviglione says, referring to health 
systems, although the same holds true for 
environmental surveys.
Europe and the United States use far more 
antibiotics by volume as well as newer antibiot-
ics compared with less affluent countries that 
typically use fewer and older generations of 
drugs, Raviglione says. That would indicate 
such countries might not yet have resistance to 
latest-generation drugs the same way Europe 
and the United States do. But there remains 
concern about the outsourcing of drug pro-
duction to developing countries, especially 
India and China, where lax enforcement of 
regulations could increase the likelihood of 
unchecked environmental releases of active 
pharmaceutical ingredients—hence studies 
such as Larsson’s work in Patancheru. The 
potential for impacts of manufacturing newer 
antibiotics in developing countries, with pos-
sible unwanted environmental releases, has not 
yet been studied, say the scientists contacted 
for this story.
Making data internationally available so 
that teams are tracking the same genes and spe-
cies in different countries may be one avenue of 
attack on the issue of antibiotic resistance. Julian 
Davies, a professor emeritus of microbiology 
and immunology at the University of British 
Columbia, and David Graham, an environ-
mental engineer at Newcastle University, have 
been working on a proposal to bring together 
members of the medical, environmental, and 
microbial research communities to address anti-
biotic resistance issues. If funded, their efforts 
could result in local centers on every continent 
working to monitor antibiotic resistance, look 
for simple solutions to preventing the spread 
of antibiotic-resistant microbes inside hospitals, 
and communicate about antibiotic resistance 
issues at an international scale.
The interdisciplinary breadth needed to 
address the many issues at hand have led to mis-
communications stemming from vocabulary, 
Graham says. Take the word transmission, he 
explains: “To a physician or engineer, transmis-
sion means migration between individuals at 
larger scales, whereas to a microbiologist trans-
mission is something at the micro-scale between 
the bacteria themselves. It took us [the diverse 
members of the team working on the proposal] 
awhile to agree upon a common language.”
But microbes have few such communi-
cation barriers, and they quickly find ways 
to communicate resistance, as plane transit 
brings countries—and antibiotic resistance 
hot spots—closer together. Some of the global 
aspects of the problem can be illustrated by 
last year’s description of NDM-1, a protein 
present on plasmids that confers antibiotic 
resistance to multiple antibiotics.
43 The mecha-
nism of resistance traveled from hospitals in 
India to the United Kingdom via patients who 
had visited the subcontinent, presumably for cheap medical treatments, and then returned 
home. Furthermore, NDM-1 has appeared in 
tap water and wastewater outside of hospital 
settings in New Delhi, according to another 
recent report in The Lancet Infectious Diseases,
44 
heightening concerns for local transmission in 
an urban environment.
Tools for the Trade
Ussery and his colleagues, while working to 
figure out antibiotic resistance transfer at a 
basic level, are also developing field tools for 
tracking antibiotic resistance genes and the 
microbes that carry them. The team includes 
computer scientists searching for simple algo-
rithms that will let researchers make fast iden-
tifications of resistance gene sequences and 
resistant microbial species.
Ussery envisions a device on every doctor’s 
desk that could take a swab from a patient 
and sequence the DNA from that sample. 
This device, connected to the Internet or with 
databases preloaded, could use the sequence to 
identify the microbes present to the genus or 
even species level, then spot genes they might 
carry for resistance to certain drugs. The test 
could potentially even predict the effectiveness 
of specific drugs in individual patients. That 
could guide doctors in prescribing treatment 
or hospitals in determining when to quaran-
tine a patient with a particularly virulent resis-
tant strain of an infectious disease. 
“Some machines are now doing 
single-molecule sequencing [of bacteria] from 
one cell. The technology is almost there,” Ussery 
says, citing manufacturer Oxford Nanopore’s 
machines that can sequence a microbe from one 
cell as being close to market-ready. 
For tracking antibiotic resistance in the 
field, these techniques could prove to be a mas-
sive boon, but they will have to become much 
less expensive than current market costs of the 
machines, comments Davies. The newest so-
called third-generation apparatuses for identify-
ing genetic codes in the blink of an eye may cut 
the cost of reading an entire genome to a tenth 
or less of current costs, but machines will still 
cost hundreds of thousands of dollars, he says, 
backed up by the price tag of Pacific Biosciences’ 
first entry to the market late last year.
Searching for Simple Answers
Even a very expensive diagnostic tool would 
save a lot of lives, Cars says, and it would also 
save antibiotics for clinical use: rapid tests 
used on a daily basis could lead to hospital 
practices that save time and money while con-
serving antibiotics for treatment. 
But new technologies are not the only tool 
that will be necessary to address all the threads 
that intertwine the problem of spreading anti-
biotic resistance, Cars and others say. Tracking 
genes in hospitals and the wild, putting poli-
cies in place to limit use of antibiotics outside 
of absolute necessity in a clinical setting—the 
wish list goes on.
And yet, in some ways, simple solutions 
seem to be in the offing. U.S. congressmen 
recently visited Denmark to learn more about 
that country’s successful transition away from 
antibiotic use for growth promotion in swine.
Contrary to stories about how Denmark’s 
agricultural sector crashed after that use of 
antibiotics completely stopped five years ago, 
Frank Møller Aarestrup of the Technical 
University of Denmark and colleagues report 
the country today continues to increase its 
exports of pigs without the help of antibiot-
ics, depending solely on improved animal 
husbandry techniques.
45 
This anecdote underscores the power of 
seemingly simple policy decisions to make 
immediate changes with promising conse-
quences. Absent such courageous steps, “it’s 
almost just a matter of time” before antibiotic 
resistance is transferred to a pathogen that mat-
ters for human health, Ussery says.  
“It’s an enormously frustrating situation,” 
says Davies, who says he feels he and his col-
leagues talk a lot about the problem without 
making much headway at the larger scale. In 
the end, he says, solutions can only come from 
convincing the general public and lawmakers 
that the time to act is now. 
Naomi Lubick is a freelance science writer based in Stockholm, 
Sweden, and Folsom, CA. She has written for Environmental 
Science & Technology, Nature, and Earth.
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